Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
Stocks in this Quantisnow insightHealth Care
Historical context for BMY
Across the 23 sessions after earlier BMY headlines, the stock closed higher 13 times and lower 10 times, with a median move of 1.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BMY | SPY |
|---|---|---|---|
| Jan 12, 2026 | Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) | -0.2% | +0.2% |
| Jan 7, 2026 | Bristol-Myers upgraded by UBS with a new price target | +4.2% | -0.3% |
| Jan 2, 2026 | Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference | -0.9% | +0.2% |
| Dec 19, 2025 | Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans | +1.6% | +0.6% |
| Dec 18, 2025 | Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026 | -0.4% | +0.8% |
| Dec 15, 2025 | Bristol-Myers upgraded by BofA Securities with a new price target | +3.6% | -0.2% |
Quantisnow market dataNYSE
BMY
Bristol-Myers Squibb Company
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for BMY
Full BMY profile on Quantisnow Follow BMY and get a push notification the moment its next story breaks.